Oryzon Genomics SA (ES:ORY) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Oryzon Genomics has reported a reduction in R&D investments and a slight increase in revenue from its own assets for Q3 2024, despite a net loss of €2.3 million. The company is preparing for a Phase III trial for vafidemstat following promising results in treating Borderline Personality Disorder, and is expanding trials for iadademstat in oncology. These developments highlight Oryzon’s focused efforts on advancing its clinical-stage programs and strengthening its patent portfolio.
For further insights into ES:ORY stock, check out TipRanks’ Stock Analysis page.
